T. Mitsudomi, S. Morita, Y. Yatabe, et al., “Gefitinib versus Cisplatin plus Docetaxel in Patients with Non-SmallCell Lung Cancer Harbouring Mutations of the Epidermal Growth Factor Receptor (WJTOG3405): An Open Label, Randomised Phase 3 Trial,” Lancet Oncology, Vol. 11, No. 2, 2010, pp. 121-128. doi:10.1016/S1470-2045(09)70364-X

has been cited by the following article:

• TITLE: Stratified Cox Regression Analysis of Survival under CIMAvax®EGF Vaccine

  AUTHORS: Carmen Viada Gonzalez, Jean-François Dupuy, Martha Fors López, Patricia Lorenzo Luaces, Camilo Rodríguez Rodríguez, Gisela González Marinello, Elia Neninger Vinagera, Beatriz García Verdecia, Bárbara Wilkinson Brito, Liana Martínez Pérez, Mayelin Troche de la Concepción, Tania Crombet-Ramos

  KEYWORDS: Stratified Cox Regression Model; Risk Factor; Non-Small Lung Cancer; Censored Data

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.8A, August 16, 2013

  ABSTRACT: Background: The Center of Molecular Immunology (CIM) is a center in Cuba devoted to the research, development and manufacturing of biotechnological products. CIMAvax?EGF is a vaccine for the treatment of non-small cell lung cancer patients (NSCL). Purpose: The aim of this work is to evaluate the effects of some potential prognostic factors on the overall survival of patients treated with CIMAvax?EGF vaccine, based on data collected in a phase II and a phase III clinical trials. Methods: The stratified Cox regression model is used to evaluate the effects of these prognostic factors, based on separate analysis for each trial, and on the combined data from both trials. Results: Patients with Performance status 0 or 1, with IV stage of tumor and male under 60 years obtain more benefit in terms of overall survival if they receive CIMAvax?EGF. Conclusions: Vaccinated group has a better performance if patients have a performance status 0 or 1, stage IV and age under 60 years. These prognostic factors influence overall survival in a positive way for those patients that received CIMAvax?EGF.